A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)

Sex: All

Ages: 18 Years – 75 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 158

Sponsor: Merck Sharp & Dohme LLC

Summary

Researchers are looking for new ways to treat active pulmonary sarcoidosis (PS). This trial will help researchers learn if a trial medicine called tulisokibart can treat symptoms of active PS. The goal of this trial is to learn if tulisokibart works better than placebo to increase the length of time until PS gets worse.

Eligibility Criteria

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has a diagnosis of sarcoidosis of ≥6 months before Screening confirmed by tissue biopsy * Has lung parenchymal involvement consistent with pulmonary sarcoidosis (PS) by chest X-ray or chest high-resolution computed tomography (HRCT) either via historical evidence or at Screening * Has active PS within 3 months before Screening Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a history of cancer and is disease free for \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07867938). StuddyBuddy aggregates publicly available trial information.